Escape Bio Overview
- Founded
-
2015
- Status
-
Out of Business
- Employees
-
44
- Latest Deal Type
-
Liquidation
Escape Bio General Information
Description
Developer of precision small molecule therapies designed to treat genetically defined subpopulations in neurodegenerative diseases. The company's therapies are a novel, orally-administered, brain-penetrant, and selective agonist of the S1P5 receptor in development for the treatment of lysosomal storage disorder Niemann-Pick type C and for Parkinson's disease, enabling the healthcare providers to treat the patients carrying the ApoE4 risk allele and improve their lives.
Contact Information
Website
www.escapebio.com
Formerly Known As
E-Scape Bio
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 4000 Shoreline Court
- Suite 400 South
- San Francisco, CA 94080
- United States
Escape Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Bankruptcy: Liquidation | 01-Sep-2022 | 00000 | Completed | Bankruptcy: Liquidation | ||
| 3. Later Stage VC (Series C) | 14-Sep-2020 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 2. Early Stage VC (Series B) | 29-Jul-2019 | $31.1M | $94.1M | 00000 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC (Series A) | 12-Jul-2017 | $63M | $63M | 0000 | Completed | Generating Revenue |
Escape Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
| Series A | 53,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 28.64% |
Escape Bio Patents
Escape Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230148214-A1 | Indazoles and azaindazoles as lrrk2 inhibitors | Pending | 06-Mar-2020 | 0000000000 | |
| AU-2020372990-A1 | Processes for preparing an s1p-receptor modulator | Pending | 31-Oct-2019 | 0000000000 | |
| CA-3159193-A1 | Processes for preparing an s1p-receptor modulator | Pending | 31-Oct-2019 | 0000000000 | |
| EP-4051684-A1 | Processes for preparing an s1p-receptor modulator | Pending | 31-Oct-2019 | 0000000000 | |
| US-20210139503-A1 | Processes for preparing an s1p-receptor modulator | Pending | 31-Oct-2019 | C07D498/04 |
Escape Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Escape Bio Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000'0 0 | 03-Jan-2019 | 000000000 | Buildings and Property |